FDA approves Merck lung disease drug acquired in $11B deal
BioPharma
Stay updated with breaking news from Acceleron Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The U.S. Food and Drug Administration on Tuesday approved Merck's treatment for adults with high blood pressure due to constriction of lung arteries, adding another...
The FDA approval marks a milestone for Merck, which acquired the pulmonary arterial hypertension treatment in 2021 through its $11.5 billion buyout of Acceleron Pharma.
The approval is a win for Merck, which is working to diversify its revenue stream as its blockbuster cancer drug Keytruda nears a loss of market exclusivity.
The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the...